Addition of cyclosporine/tacrolimus for pediatric relapsed lupus nephritis during mycophenolate mofetil maintenance...

Area of Science:

• Pediatric Nephrology
• Immunosuppressive Therapy
• Autoimmune Diseases

Background:

• Proliferative lupus nephritis (PLN) is a severe complication of systemic lupus erythematosus in children.
• Maintenance therapy is crucial to prevent disease relapse and preserve renal function.
• Mycophenolate mofetil (MMF) is a common maintenance therapy, but some patients may relapse or show suboptimal response.

Purpose of the Study:

• To evaluate the efficacy and safety of adding low-dose cyclosporine (CsA) or tacrolimus (Tac) to MMF maintenance therapy in pediatric patients with PLN.
• To assess the rates of renal remission and clinical response over a 3-year period.
• To identify any severe adverse events associated with the combined immunosuppressive regimen.

Main Methods:

• Eleven children with PLN who relapsed on MMF maintenance therapy received add-on low-dose CsA or Tac.
• Renal remission was assessed at multiple time points: 3 and 6 months, and 1, 2, and 3 years post-intervention.
• Adverse events were systematically recorded throughout the study period.

Main Results:

• High clinical response rates were observed, reaching 100% at 6 months and sustained through 3 years.
• Complete renal remission rates varied, with a notable increase to 71.4% by the 3-year mark.
• No severe adverse events were reported in any of the participating patients.

Conclusions:

• The combination of low-dose CsA/Tac with MMF demonstrates a promising therapeutic effect for achieving renal remission in pediatric PLN.
• This regimen is associated with acceptable safety profiles, making it a viable option for managing relapsed or inadequately treated lupus nephritis.
• The findings support the use of this combination therapy in children with PLN requiring enhanced maintenance strategies.